Next Generation Sequencing for HIV Drug Resistance Testing, 2nd Edition

Dear Colleagues,

Drug resistance remains a global challenge in the fight against the HIV pandemic, as recognized by the World Health Organization and the United Nations. Wherever feasible, guidelines recommend to particularly test for drug resistance before and during antiretroviral therapy to guide regimen selection. In circumstances where it is less viable, such testing is used only in specific populations, and where it is entirely unattainable, testing is generally used for public health surveillance.

Sanger sequencing, available since the 1970s, has conventionally been used for HIV drug-resistance testing in clinical care and research. In recent times, the newly developed next-generation sequencing (NGS) methods are being increasingly used in diverse circumstances, including HIV drug-resistance testing. However, due to several financial, infrastructural, and logistical challenges, it has not yet been determined how feasible it would be to replace Sanger sequencing with NGS for HIV drug-resistance testing. Thus, the logistics of resistance testing involving newly FDA-approved antiretroviral drugs, resistance patterns in different HIV subtypes, and their archival patterns in the viral reservoir are research priorities.

For this Special Issue, we cordially invite researchers working in the field of HIV drug resistance to submit their valuable manuscripts that report on their latest findings, summarize the status of the field, and highlight the related opportunities and challenges.

Dr. Guinevere Q. Lee
Guest Editor

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Viruses is an international peer-reviewed open access monthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2600 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

• NGS
• HIV drug resistance
• HIV genetic diversity
• HIV subtypes

• Next Generation Sequencing for HIV Drug Resistance Testing in Viruses (11 articles)